Pressmeddelanden från AstraZeneca

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Imfinzi+Imjudo improves PFS in early liver cancer 31 mar 08:04

Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia 27 mar 08:10

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD 16 mar 08:07

Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers 10 mar 12:02

Notice of Annual General Meeting 09 mar 07:35

Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer 27 feb 08:03

Strensiq approved for restricted reimbursement in Sweden 25 feb 08:01

Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission 24 feb 12:02

Annual Financial Report 20 feb 08:39

Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting 13 feb 08:06

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for Breztri in patients with uncontrolled asthma published in The Lancet Respiratory Medicine 10 feb 08:00

Resultat för AstraZeneca: Helåret samt fjärde kvartalet 2025 03 feb 08:34

Datroway granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy 03 feb 08:08

Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus 02 feb 08:09

Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers 02 feb 08:05

AstraZeneca begins trading on the New York Stock Exchange 30 jan 08:05

AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals 29 jan 10:57

AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines 20 jan 08:05

AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange 08 jan 08:00

AstraZeneca appoints Joris Silon as Head of Investor Relations 06 jan 08:00

Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity 22 dec 2025 08:30

Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer 22 dec 2025 08:00

Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer 16 dec 2025 08:10

Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus 16 dec 2025 08:07

Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer 04 dec 2025 08:13

AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH 02 dec 2025 08:31

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension 26 nov 2025 08:01

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers 24 nov 2025 08:01

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth 20 nov 2025 08:00

Koselugo approved in the US for adults with neurofibromatosis type 1 10 nov 2025 08:06

Bax24 Phase III Trial Full Results 10 nov 2025 08:00

Regeringen, AstraZeneca, Scania och RISE i nytt samarbete kring grön teknik 06 nov 2025 08:00

Resultat för AstraZeneca: 9 månader samt tredje kvartalet 2025 03 nov 2025 17:02

Result of General Meeting held on 3 November 2025 30 okt 2025 17:31

Gefurulimab demonstrates statistically significant, clinically meaningful improvement in MG-ADL at week 26, clinically meaningful improvement as early as week one in gMG adults in PREVAIL PhIII trial 29 okt 2025 19:02

Alexion data presented at 2025 AANEM Annual Meeting and MGFA Scientific Session underscores pioneering C5 inhibition leadership in gMG 28 okt 2025 08:00

Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1 22 okt 2025 08:01

Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps 20 okt 2025 08:19

Tezspire approved in the US for chronic rhinosinusitis with nasal polyps 20 okt 2025 08:06

Saphnelo subcutaneous self-administration recommended for approval in EU by CHMP for systemic lupus erythematosus 19 okt 2025 08:35

Datroway demonstrated an unprecedented median OS improvement of five months vs. chemotherapy for patients with metastatic TNBC for whom immunotherapy was not an option in TROPION-Breast02 18 okt 2025 16:35

Enhertu reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial 18 okt 2025 16:30

Enhertu followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial 17 okt 2025 14:25

Imfinzi regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial 17 okt 2025 14:10

Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial 13 okt 2025 08:06

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO 13 okt 2025 08:01

AstraZeneca announces historic agreement with US Government to lower the cost of medicines for American patients 09 okt 2025 18:33

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs 07 okt 2025 08:00

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension 06 okt 2025 08:33

Datroway improved OS and PFS in TROPION-Breast02 29 sep 2025 08:30

Enhertu improved IDFS in early BC in DB-05 29 sep 2025 08:02

AstraZeneca to harmonise its listing structure across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange 24 sep 2025 08:09

Enhertu plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer 22 sep 2025 08:08

Koselugo recommended for approval in the EU by CHMP for plexiform neurofibromas in adults with neurofibromatosis type 1 22 sep 2025 08:00

Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps 19 sep 2025 08:00

Alexion data presented at ECTRIMS 2025 reinforces Ultomiris leadership in transforming care for patients with NMOSD 17 sep 2025 08:06

Saphnelo self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis 17 sep 2025 08:02

Update on the RESOLUTE Phase III trial for Fasenra in chronic obstructive pulmonary disease 07 sep 2025 08:16

Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer 30 aug 2025 16:16

Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial 29 jul 2025 08:00

Resultat för AstraZeneca: första halvåret samt andra kvartalet 2025 28 jul 2025 08:03

Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers 25 jul 2025 12:50

Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine using next-generation propellant with near-zero Global Warming Potential 24 jul 2025 08:05

Gefurulimab nanobody met Phase III endpoints 22 jul 2025 08:02

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D 21 jul 2025 08:07

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer 16 jul 2025 08:05

Update on CARES Phase III clinical programme of anselamimab in light chain amyloidosis 14 jul 2025 08:09

Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension 04 jul 2025 08:03

Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer 24 jun 2025 08:01

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer 23 jun 2025 08:04

Alexion data presented at EAN 2025 highlights its leadership and commitment to improving patient outcomes in rare neurological diseases 13 jun 2025 10:30

AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research 06 jun 2025 08:03

Fixed-duration -based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting 02 jun 2025 14:06

Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial 01 jun 2025 14:05

Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial 01 jun 2025 14:00

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial 27 maj 2025 08:01

Imfinzi recommended for approval in the EU by CHMP as first and only perioperative immunotherapy for muscle-invasive bladder cancer 21 maj 2025 08:00

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer 20 maj 2025 08:07

Acquisition of EsoBiotec completed 19 maj 2025 18:18

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for Airsupra as standard of care for as-needed rescue treatment in asthma 13 maj 2025 08:01

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025 12 maj 2025 08:05

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential 09 maj 2025 08:00

Imfinzi regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial 07 maj 2025 08:30

Enhertu improved pCR in early-stage breast cancer 06 maj 2025 08:04

Calquence plus chemoimmunotherapy approved in the EU as first and only BTK inhibitor for 1st-line mantle cell lymphoma 02 maj 2025 08:05

Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma 29 apr 2025 08:10

Fixed-duration -based regimens recommended for approval in the EU by CHMP for 1st-line chronic lymphocytic leukaemia 29 apr 2025 08:05

Update on CAPItello-280 Phase III trial of Truqap in metastatic castration-resistant prostate cancer 29 apr 2025 08:00

Resultat för AstraZeneca: Q1 2025 22 apr 2025 08:00

Enhertu combination improved PFS in 1L HER2+ mBC 11 apr 2025 18:30

Results of Annual General Meeting held on 11 April 2025 08 apr 2025 08:01

AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025 04 apr 2025 08:06

Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer 04 apr 2025 08:03

Enhertu approved in the EU as first HER2-directed therapy for patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer following at least one endocrine therapy 31 mar 2025 18:05

AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial 31 mar 2025 08:13

Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma 31 mar 2025 08:06

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer 27 mar 2025 08:06

Alexion data presented at the 2025 AAN Annual Meeting highlight advancements in improving care for rare neurological diseases 25 mar 2025 08:05

New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings 21 mar 2025 12:09

AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing